Rabourn Amy Zaremba Sells 2,816 Shares of Opus Genetics (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD) insider Rabourn Amy Zaremba sold 2,816 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $5.25, for a total value of $14,784.00. Following the transaction, the insider owned 190,312 shares of the company’s stock, valued at approximately $999,138. The trade was a 1.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Opus Genetics Stock Down 1.7%

IRD stock opened at $4.58 on Friday. Opus Genetics, Inc. has a twelve month low of $0.65 and a twelve month high of $5.30. The firm has a market cap of $325.87 million, a price-to-earnings ratio of -5.59 and a beta of 0.45. The business’s fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $2.42.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IRD shares. Lifesci Capital upgraded shares of Opus Genetics to a “strong-buy” rating in a research note on Thursday, February 12th. Wall Street Zen raised shares of Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, March 1st. upgraded Opus Genetics to a “strong-buy” rating in a report on Monday, December 1st. Craig Hallum set a $9.00 price objective on Opus Genetics and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Finally, Wedbush raised their price objective on Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Opus Genetics presently has an average rating of “Moderate Buy” and an average target price of $9.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRD. Balyasny Asset Management L.P. purchased a new position in Opus Genetics during the 4th quarter valued at about $5,463,000. BIOS Capital Management LP boosted its stake in shares of Opus Genetics by 270.1% during the second quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock valued at $3,462,000 after purchasing an additional 2,688,180 shares in the last quarter. Millennium Management LLC purchased a new position in Opus Genetics during the fourth quarter valued at approximately $4,025,000. Nantahala Capital Management LLC raised its stake in Opus Genetics by 42.9% in the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after buying an additional 1,435,407 shares in the last quarter. Finally, Mink Brook Asset Management LLC lifted its holdings in Opus Genetics by 34.5% during the fourth quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock worth $3,348,000 after buying an additional 427,684 shares during the period. 14.97% of the stock is currently owned by institutional investors.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.